Epidemiology of Schistosomiasis in the People’s Republic of China, 2004

National Institute of Parasitic Diseases, Shanghai, People's Republic of China.
Emerging Infectious Diseases (Impact Factor: 7.33). 11/2007; 13(10):1470-6. DOI: 10.3201/eid1310.061423
Source: PubMed

ABSTRACT Results from the third nationwide cluster sampling survey on the epidemiology of schistosomiasis in the People's Republic of China, conducted by the Ministry of Health in 2004, are presented. A stratified cluster random sampling technique was used, and 239 villages were selected in 7 provinces where Schistosoma japonicum remains endemic. A total of 250,987 residents 6-65 years of age were included in the survey. Estimated prevalence rates in the provinces of Hunan, Hubei, Jiangxi, Anhui, Yunnan, Sichuan, and Jiangsu were 4.2%, 3.8%, 3.1%, 2.2%, 1.7%, 0.9%, and 0.3%, respectively. The highest prevalence rates were in the lake and marshland region (3.8%) and the lowest rates were in the plain region with waterway networks (0.06%). Extrapolation to all residents in schistosome-endemic areas indicated 726,112 infections. This indicates a reduction of 16.1% compared with a nationwide survey conducted in 1995. However, human infection rates increased by 3.9% in settings where transmission is ongoing.


Available from: Guojing Yang, Feb 04, 2015
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: The Chinese national surveillance system showed that the risk of Schistosoma japonicum infection fluctuated temporally. This dynamical change might indicate periodicity of the disease, and its understanding could significantly improve targeted interventions to reduce the burden of schistosomiasis. The goal of this study was to investigate how the schistosomiasis risk varied temporally and spatially in recent years. Parasitological data were obtained through repeated cross-sectional surveys that were carried out during 1997-2010 in Anhui Province, East China. A multivariate autoregressive model, combined with principal oscillation pattern (POP) analysis, was used to evaluate the spatio-temporal variation of schistosomiasis risk. Results showed that the temporal changes of schistosomiasis risk in the study area could be decomposed into two sustained damped oscillatory modes with estimated period of approximately 2.5 years. The POPs associated with these oscillatory components showed that the pattern near the Yangtze River varied markedly and that the disease risk appeared to evolve in a Southwest/Northeast orientation. The POP coefficients showed decreasing tendency until 2001, then increasing during 2002-2005 and decaying afterwards. The POP analysis characterized the variations of schistosomiasis risk over space and time and demonstrated that the disease mainly varied temporally along the Yangtze River. The schistosomiasis risk declined periodically with a temporal fluctuation. Whether it resulted from previous national control strategies on schistosomiasis needs further investigations.
    PLoS Neglected Tropical Diseases 04/2015; 9(4):e0003715. DOI:10.1371/journal.pntd.0003715 · 4.49 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Schistosomiasis has decreased significantly in prevalence and intensity of infection in China, thus more accurate and sensitive methods are desperately needed for the further control of schistosomiasis. The present work aimed to assess the utility of the loop-mediated isothermal amplification (LAMP) for detection of light intensity infection or false-negative patients and patients post-treatment, targeting the highly repetitive retrotransposon SjR2 of Schistosoma japonicum. LAMP was first assessed in rabbits with low intensity infection (EPG<10). Then 110 patient sera from Hunan Province, China, and 47 sera after treatment by praziquantel were used to evaluate the diagnostic validity of LAMP. Meanwhile, 42 sera from healthy individuals in a non-endemic area, and 60 sera from "healthy" residents who were identified as being negative for feces examination and immuno-methods in an endemic area were also examined. The results showed that LAMP could detect S. japonicum DNA in sera from rabbits at 3rd day post-infection. Following administration of praziquantel, the S. japonicum DNA in rabbit sera became negative at 10 weeks post-treatment. Of 110 sera from patients, LAMP showed 95.5% sensitivity, and even for 41 patients with less than 10 EPG, the sensitivity of LAMP still reached to 95.1%. For 47 patients after treatment, the negative conversion rate of S. japonicum DNA in patient sera increased from 23.4%, 61.7% to 83.0% at 3 months, 6 months and 9 months post-treatment, respectively. No false-positive result was obtained for 42 human sera from non-endemic area, while for the 60 "healthy" individuals from endemic area, 10 (16.7%) individuals were positive by LAMP, which suggested that these individuals might be false-negative patients. The present study demonstrated that the LAMP assay is sensitive, specific, and affordable, which would help reduce schistosomiasis transmission through targeted treatment of individuals, particularly for those with negative stool examinations who may yet remain infected. The LAMP assay may provide a potential tool to support schistosomiasis control and elimination strategies.
    PLoS Neglected Tropical Diseases 04/2015; 9(4):e0003668. DOI:10.1371/journal.pntd.0003668 · 4.49 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Mass drug administration (MDA) is a means of delivering safe and inexpensive essential medicines based on the principles of preventive chemotherapy, where populations or sub-populations are offered treatment without individual diagnosis. High-coverage MDA in endemic areas aims to prevent and alleviate symptoms and morbidity on the one hand and can reduce transmission on the other, together improving global health. MDA is the recommended strategy of the World Health Organisation to control or eliminate several neglected tropical diseases (NTDs). More than 700 million people now receive these essential NTD medicines annually. The combined cost of integrated NTD MDA has been calculated to be in the order of $0.50 per person per year. Activities have recently been expanded due, in part, to the proposed attempt to eliminate certain NTDs in the coming two decades. More than 1.9 billion people need to receive MDA annually across several years if these targets are to be met. Such extensive coverage will require additional avenues of financial support, expanded monitoring and evaluation focusing on impact and drug efficacy, as well as new diagnostic tools and social science strategies to encourage adherence. MDA is a means to help reduce the burden of disease, and hence poverty, among the poorest sector of populations. It has already made significant improvements to global health and productivity and has the potential for further successes, particularly where incorporated into sanitation and education programmes. However logistical, financial and biological challenges remain.
    Philosophical Transactions of The Royal Society B Biological Sciences 01/2014; 369(1645):20130434. DOI:10.1098/rstb.2013.0434 · 6.31 Impact Factor